Conversations Contributors - Marla Weston

Marla Weston, PhD, RN, FAAN, chief executive officer (CEO) of the American Nurses Association (ANA), is a distinguished and visionary leader for nursing, who has dedicated her career to improving the work and public policy environment for nurses and the quality of care for patients.


Historically, vaccines have had an unmatched impact on improving public health. Looking ahead, what are the biggest obstacles and exciting opportunities in the field?

Contributors Respond

PhRMA Conversations

08.29.13 | By

As we’ve previously noted on the Catalyst, medication adherence continues to be a serious challenge with significant consequences to patient health and costs associated with acute care, hospitalizations and surgery. Today, nearly 145 million Americans suffer from chronic disease, but only one-third take their medications as prescribed.

Conversations Contributors - Jon Easter

Jon Easter, BSPharm, RPh, is senior director, delivery and payment reform, at GlaxoSmithKline (GSK). His primary focus is health care transformation and the health information technology (HIT) policy environment, where he works to maximize its value to enable better health care quality, enhance the US health care delivery system, and ultimately improve patient outcomes.

Conversations Contributors - Sally Greenberg

Sally Greenberg joined the National Consumers League as Executive Director on October 1, 2007. The League’s focus is on five key priority areas: fraud, child labor, LifeSmarts, health care, especially the safe use of medications and medication adherence, and food safety and nutrition.

Conversations Contributors - Joel White

Joel White is the Executive Director of the Council for Affordable Health Coverage (  CAHC is a broad-based alliance with a singular focus:  bringing down the cost of health care for all Americans.  CAHC’s membership reflects a broad range of interests—organizations representing small and large employers, manufacturers, retailers, insurers, brokers and agents, physician and patient organizations and individual consumers. 


A recent study found that nearly two-thirds of Americans do not adhere to their medicines as prescribed. How do we address this challenge?

Contributors Respond

Conversations: Clinical Trial Data, Transparency and Patient Privacy

08.20.13 | By

Bringing a medicine to patients, from discovery through FDA review, is a lengthy, costly and sometimes unpredictable process. On average, it takes 10-15 years and an investment of more than $1 billion. As noted previously on the Catalyst, only one out of 5,000-10,000 potential new medicines make it through the multiple and rigorous pre-clinical and clinical trials phases and is ultimately approved by the FDA for patient use.

Public-Private Partnerships and Neurological Diseases

08.16.13 | By

Despite the great medical advances of the last century, there is still a lot of work to be done when it comes to developing medications and treatments to deal with neurological disorders such as Parkinson’s disease. These conditions pose vexing challenges for researchers trying to unlock the secrets that will improve the lives of millions living with the daily challenges that neurological diseases pose.

Conversations Contributors - Douglas Peddicord

With policy expertise in the conduct and regulatory oversight of clinical trials, Dr. Peddicord serves as Executive Director of the Association of Clinical Research Organizations (ACRO).


Subscribe to RSS - conversations